Clinical Trials | March 23, 2023
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Transformation to pure-play Innovative Medicines company nears completion
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Subscribe To Our Newsletter & Stay Updated
